Synklino Announces Successful Outcome of Scientific Advice Meeting with MHRA in the UK

Synklino, a Danish biotech company developing drugs to treat chronic viral infections, has decided to focus the development of SYN002 on eliminating CMV in infected organs prior to transplantation (ex vivo).

Synklino focuses SYN002 development on ex-vivo organ therapy

Synklino, a Danish biotech company developing drugs to treat chronic viral infections, has decided to focus the development of SYN002 on eliminating CMV in infected organs prior to transplantation (ex vivo).